Bexarotene
Back to searchMolecule Structure
Scientific Name
Bexarotene
Description of the Drug
Bexarotene is a retinoid drug used for cutaneous manifestations of T-cell lymphoma in patients who have not responded well to previous systemic therapy.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00307
http://www.drugbank.ca/drugs/DB00307
Brand Name(s)
Bexarotene, Targretin, Targretine
Company Owner(s)
Bausch Health Ireland Ltd, Amneal Pharmaceuticals Of Ny Llc, Upsher Smith Laboratories Llc, Ani Pharmaceuticals Inc, Teva Pharmaceuticals Usa, Amneal Pharmaceuticals Llc, Bionpharma Inc, Hikma Pharmaceuticals Usa Inc, Valeant Pharmaceuticals Luxembourg Sarl
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Retinoid X receptor | PROTEIN FAMILY | AGONIST | CHEMBL2363070 |
Clinical Trial(s)
Unichem Links
| Atlas | targretin | |
| SureChEMBL | SCHEMBL9025 | |
| PharmGKB | PA164752250 | |
| Human Metabolome Database | HMDB0014452 | |
| DrugBank | DB00307 | |
| PubChem: Thomson Pharma | 14876119 | |
| PubChem | 82146 | |
| Mcule | MCULE-3783114634 | |
| LINCS | LSM-45378 | |
| Nikkaji | J612.549B | |
| PDBe | 9RA | |
| BindingDB | 50032675 | |
| EPA CompTox Dashboard | DTXSID1040619 | |
| DrugCentral | 361 | |
| ChemicalBook | CB6506670 | |
| Guide to Pharmacology | 2807 | |
| rxnorm | TARGRETIN | BEXAROTENE |
| PubChem: Drugs of the Future | 87550948 | |
| ChEBI | 50859 | |
| ZINC | ZINC000001539579 |
